Compositions of boswellic acids derived from Boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
AssigneeSami Labs Limited
InventorsMuhammed Majeed, Vladimir Badmaev
Life of this patent
Estimating the term…
Abstract
A method of treatment of lymphoproliferative and autoimmune disorders with a new composition of four boswellic acids including β-boswellic acid, 3-O-acetyl-β-boswellic acid, 11-keto-β-boswellic acid, and 3-O-acetyl-11-keto-β-boswellic acid. Boswellic acids of invention have been obtained in a novel industrial process from the gum resin of Boswellia serrata tree, providing standardized composition which inhibits DNA, RNA and protein synthesis of the target cell without cytotoxic effects. The composition of invention provides advantage of irreversible cytostatic therapy, equivalent to biological effects of a cytotoxic therapy without killing body cells.
Claims7
1-85. (canceled)
A method for the treatment of leukemia, comprising administering an effective amount of a composition comprising boswellic acids consisting essentially of
- β-boswellic acid of at least 12% by weight;
- acetyl-β-boswellic acid of at least 5% by weight;
- 11-keto-β-boswellic acid of at least 1% by weight;
- and
- acetyl-11-keto-β-boswellic acid of at least 1% by weight.
Dependencies are inferred from the claim text.